Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.71 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.70 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.62 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | FAP | Q12884 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509241 | 1.00 | DPP4 (0.71) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1509225 | 0.89 | DPP4 (0.65) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL8362642 | 0.86 | DPP4 (0.62) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL7061963 | 0.85 | DPP4 (0.71) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL1509247 | 0.85 | DPP4 (0.71) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL20781026 | 0.83 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL8325488 | 0.82 | DPP4 (0.70) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL12767539 | 0.81 | DPP4 (0.68) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL8243586 | 0.81 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1071529 | 0.80 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226324-A1 | BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES FOR USE IN THE TREATMENT OF DIABETES TYPE II | Merck Sharp & Dohme Corp. (US) | 2010-09-08 | — | — | EP | disclosed |